Form 4: Tango Therapeutics Director Boosts Stake with Equity Grant

Tango Therapeutics Director Sung Lee receives 10,000 restricted stock units and 60,000 stock options.

Summary

• Sung Lee, a Director at Tango Therapeutics, Inc. (TNGX), acquired 10,000 shares of common stock in the form of Restricted Stock Units (RSUs) on January 2, 2026.
• Each RSU represents a contingent right to receive one share of Common Stock and will vest in three substantially equal annual installments, subject to continuous service.
• Additionally, Mr. Lee acquired 60,000 stock options with an exercise price of $8.93 per share on the same date.
• These stock options will vest and become exercisable in 36 substantially equal monthly installments over a three-year period, also subject to continuous service.
• The expiration date for the stock options is January 2, 2036.

Sentiment

Score: 7

Explanation: The filing indicates a positive sentiment as a director is increasing their stake in the company through equity compensation, aligning their interests with shareholders and signaling confidence. This is a standard, positive corporate action.

Positives

• The acquisition of equity by a director aligns their interests with those of shareholders, indicating confidence in the company's future.
• Equity compensation, such as RSUs and stock options, serves as a strong incentive for long-term commitment and performance from key personnel.

Negatives

• The shares and options are subject to vesting schedules, meaning the director does not immediately have full ownership or exercisable rights.
• The value of the compensation is tied to the future performance of Tango Therapeutics' stock, introducing market risk.

Risks

• The value of the acquired restricted stock units and stock options is subject to the inherent volatility and performance of Tango Therapeutics' common stock.
• Vesting of both the RSUs and stock options is contingent upon the reporting person's continuous service with the Issuer, posing a risk of forfeiture if service is terminated.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend over three years, indicating an expectation of continued service from Director Sung Lee and a long-term alignment of interests.

Industry Context

This Form 4 filing reflects a standard practice of executive and director compensation in the biotechnology and pharmaceutical industry, where equity grants are commonly used to attract, retain, and incentivize key personnel by linking their financial success to the company's long-term performance.

Comparison to Industry Standards

• The use of restricted stock units and stock options as a form of compensation for directors is a common practice across the biotechnology and broader public company landscape, aligning with industry standards for executive incentives.
• The vesting periods (three years for RSUs and monthly over three years for options) are typical for long-term incentive plans designed to encourage sustained commitment and performance, comparable to similar grants at companies like Moderna or BioNTech for their directors.

Related Party Transactions

• The transaction involves the issuance of equity compensation (Restricted Stock Units and Stock Options) to Sung Lee, a Director of Tango Therapeutics, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of a director's interests with shareholder value through equity ownership.
• Employees: May signal stability and confidence in the company's leadership and future direction.
• Director (Sung Lee): Receives significant long-term equity incentives, contingent on continued service and company performance.

Next Steps

• Director Sung Lee's continued service with Tango Therapeutics, Inc. is required for the vesting of the granted RSUs and stock options.
• The RSUs will vest in three substantially equal annual installments following the grant date.
• The stock options will vest in 36 substantially equal monthly installments over a three-year period following the grant date.

Key Dates

Keywords

Tango Therapeutics, TNGX, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant